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Summary
For genetic counseling and predictive testing in families
with inherited breast-ovarian cancer, penetrances and
expressions of the underlying mutations should be
known. We have previously reported two BRCA1 foun-
der mutations in the Norwegian population. Index cases
for the present study were found two different ways:
through a series of consecutive ovarian cancers (n =
) and through our family cancer clinic ( ). Al-16 n = 14
together, 20 of the patients had BRCA1 1675delA, and
10 had 1135insA. Their relatives were described with
respect to absence/presence of breast and/or ovarian
cancer. Of 133 living female relatives, 83 (62%) were
tested for the presence of a mutation. No difference, in
penetrance and expression, between the two mutations
were found, whereas differences according to method of
ascertainment were seen. The overall findings were that
disease started to occur at age 30 years and that by age
50 years 48% of the mutation-carrying women had ex-
perienced breast and/or ovarian cancer. More ovarian
cancers than breast cancers were recorded. Both pene-
trance and expression (breast cancer vs. ovarian cancer)
were different from those in reports of the Ashkenazi
founder mutations. Whether the reported differences re-
flect true differences and/or methodological problems is
discussed. An observed excess of mutation carriers could
not be accounted for by methodological problems; pos-
sible explanations were a “true” low penetrance or pref-
erential segregation.
Introduction
The majority of inherited breast-ovarian cancer and in-
herited ovarian cancer (MIM 113705) is caused by mu-
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tations in the BRCA1 gene (Easton et al. 1995; Narod
et al. 1995; Liede et al. 1998). The reported lifetime
risks for breast and/or ovarian cancer in female BRCA1-
mutation carriers vary from 36% to 95% (Easton et al.
1995; Fodor et al. 1998). It is not clear whether this is
due to ascertainment problems in the series analyzed,
true differences between penetrance of different muta-
tions, or modifying factors (environmental or genetic)
in separate populations (Narod et al. 1995; Katsouyanni
et al. 1997). In addition, it is debated whether the ratio
between breast and ovarian cancer varies according to
the position of the mutation within the gene (Easton et
al. 1995; Gayther et al. 1995).
We have approached the problem by describing
BRCA1 founder mutations in the Norwegian popula-
tion. Two such are presently known: 1675delA (Dørum
et al. 1997) and 1135insA (Andersen et al. 1996). Both
result in frameshift and stop in exon 11. 1675delA is
most frequent and has been prospectively demonstrated
as a shared BRCA1 haplotype among affected families.
Today’s living kindreds with this haplotype represent
branches of one extensive family (for details, see Dørum
et al. 1997). Preliminary data suggest that the families
with 1135insA also share one BRCA1 haplotype. There
has been a large number of meioses since the founder
person living 20–30 generations ago. All index cases in
this report are included in the Breast Cancer Information
Core database. Consequently, the families todaymay not
share genetic variation outside the BRCA1 haplotype
that they have in common. They live geographically sep-
arated. This gives an opportunity to assess the pene-
trance of the mutation-bearing haplotype. It does not,
however, solve the problems related to ascertainment.
We here describe what we have observed in kindreds
with the two Norwegian founder mutations.
Patients and Methods
Identification of Families
Family cancer-clinic series.—Families were either self-
referred or referred by a physician and were included if
they had (a) one member with ovarian cancer who had
one first-degree relative (or second-degree relative,
through a male) with ovarian cancer or breast cancer at
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Table 1
General Data on Group Studied
NO. OF MUTATIONS DEMONSTRATED (NO. OF INDEX CASES)/





Total1675delA 1135insA 1675delA 1135insA
No. of families 11 5 9 5 30
No. of cases of breast cancer:
Alive 7(2)/0/6 0/0/0 3(3)/2/2 2(5)/1/2 12(10)/3a/10
Dead 0/0/13 0/0/5 0/0/15 0/0/6 0/0/39
No. of cases of ovarian cancer:
Alive 2(11)/0/2 2(5)/0/0 1(6)/0/2 0(1)/1/0 5(23)/1a/4
Dead 0/0/25 0/0/9 0/0/18 0/0/8 0/0/60
No. of unaffected sisters:
Alive 9/9/16 11/7/11 8/9/8 2/5/1 30/30/36
Dead 0/0/8 0/0/5 0/0/11 0/0/4 0/0/28
No. of women:b
Alive 16(11)/9/24 12(5)/7/11 11(9)/11/12 4(5)/7/3 43(30)34/50
Dead 0/0/45 0/0/18 0/0/44 0/0/16 0/0/123
Overallb 16(11)/9/69 12(5)/7/29 11(9)/11/56 4(5)/7/19 43(30)/34/173
a Mutation-negative phenocopies.
b The total number of women with breast and/or ovarian cancer is less than the sum of such cases because
11 (including 3 index cases) had experienced both types of cancer.
age !60 years of age and/or (b) one member with both
breast cancer at age !60 years of age and ovarian cancer
(for details, see Møller et al. 1998). DNA from affected
individuals in 222 separate breast-ovarian cancer kin-
dreds were examined. We found nine families that had
BRCA1 1675delA and five families that had 1135insA.
Consecutive ovarian-cancer series.—A series of 727
consecutive ovarian-cancer patients from a defined ge-
ographic area (southern Norway) from May 1993–Jan-
uary 1996 were invited to participate. After informed
consent was given, we obtained blood samples from 615
patients and demonstrated 1675delA in 11 of the fam-
ilies and 1135insA in 5 of the families. The families from
the two initial reports (Andersen et al. 1996; Dørum et
al. 1997) are included in the present report.
Index Patients
In the family cancer-clinic series, one index patient per
family was identified, who was either the referred pa-
tient, if affected, or the closest related affected relative
(or the younger/youngest if the family contained two or
more affected same-degree relatives). Of the consecutive
ovarian-cancer families, 15 had one index case each.One
family had three incident cases included in the series.
The first case encountered was considered to be the index
case, and the family was counted once only. Index pa-
tients are identified in all tables if included there, and
the effect of inclusion/exclusion from the analyses is
discussed.
Pedigree Extension
The pedigrees were extended in all directions. Re-
ported cancers were verified whenever possible. Under
the assumption that dominantly inherited breast-ovarian
cancer affected the families, the highest penetrance (i.e.,
the lowest number of unaffected female obligate carriers)
was determined in each family. All living affected indi-
viduals or obligate carriers were approached to verify
carrier status by testing. Subsequently, all sisters and
adult daughters of demonstrated carriers, untested af-
fected individuals, and obligate carriers were invited to
participate in predictive mutation testing. All procedures
were performed in a health-service setting and according
to Norwegian legislation. Relatives were approached
through the index patients. Written informed consent
was obtained for all predictive testing. All results were
included in medical files. The present report reflects the
information filed as of July 1, 1998.
Statistical Analyses
Actuarial calculations of age-related penetrances were
performed by the Kaplan-Meier algorithm in the SPSS
computer program. Each person was censored at either
last observation or death. Thirteen women who had pro-
phylactic oophorectomy were censored at the date of
oophorectomy, in calculations including ovarian cancer
as event. None of the women had undergone prophy-
lactic mastectomy. In each calculation, events were con-
sidered at the date of demonstrated disease. In historical
cases in which age at diagnosis could not be determined,
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Figure 1 Age-related penetrances of BRCA1 1675delA (thicker
line) and 1135insA (thinner line) in mutation carriers (demonstrated,
affected, or obligate). Index cases are not included. a, Breast and/or
ovarian cancer (whichever came first) scored as event. b,Ovarian can-
cer scored as event (breast cancer considered as unaffected). c, Breast
cancer scored as event (ovarian cancer considered as unaffected).
age at death was used. Events were considered in three
ways: as breast or ovarian cancer (whichever came first),
as ovarian cancer (with breast cancer considered as un-
affected), or as breast cancer (with ovarian cancer con-
sidered as unaffected). Since both ovarian cancer and
breast cancer are associated with BRCA1 mutations,
censoring for the one when considering the other as
event implies the problem of informative censoring (Col-
lett 1994, p. 274); because both expressions are lethal
and the patients inevitably are censored at death, this
cannot be avoided. Censoring at age at diagnosis as well
as at age of death was employed (see the Informative
Censoring subsection, below).
For the analyses of penetrances, we included all living
or dead female mutation carriers (either as demonstrated
by either mutation testing or affected state or as iden-
tified as unaffected obligate carriers). In addition, we
included all of their sisters, as described below.
Contralateral breast cancer was not considered. Oc-
currences of multiple primary tumors (bilateral breast
or breastovarian) were not addressed.
As detailed in the Results section (see below), the series
were initially examined for differences related to ascer-
tainment criteria and the nature of themutation. Because
such differences were not found, the series were grouped
together as one series for further analyses.
Phenocopies were expected, both as in-married car-
riers of distinct mutations, in the family cancer-clinic
series, and as sporadic age-related cancers, in both series.
All phenocopies demonstrated were young and in the
family cancer-clinic series, as would be expected if they
are caused by in-married mutations (see Discussion be-
low). Sporadic age-related cancers were expected to oc-
cur at later ages. We stopped the final analysis of pen-
etrance at age 69 years, thereby excluding the older
putative sporadic cancers, and we considered all cal-
culated penetrances at 150 years of age to be possibly
influenced by the presence of phenocopies and by fluc-
tuations in small numbers.
Mutation Analyses
Peripheral ethylenediaminetetraacetate-treated blood
was collected, and DNA was extracted from frozen
blood by means of the Nucleon kit (Amersham Life
Sciences).
Fragments analysis.—50 ng of sample DNA was used
for a multiplex PCR-based fragment analysis. The re-
action was performed in 50 ml at pH 8.3, containing 0.1
M Tris, 0.5 M KCl, and 1.5 mM MgCl2, 1 mM of each
dNTP, 50 pmol of each of the four primers (BRCA1A,
BRCA1B [for analysis of a fragment containing
1135insA], 1675U, and 1675L [for analysis of a frag-
ment containing 1675delA]; MedProbe), and 1 unit of
Taq polymerase produced in house. The 30 PCR cycles
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Figure 2 Age-related penetrances of BRCA1 1675delA and
1135insA in mutation carriers (demonstrated, affected, or obligate).
Consecutive ovarian-cancer series (thicker line) and family cancer-
clinic series (thinner line). Index cases are not included. a, Breast and/
or ovarian cancer (whichever came first) scored as event. b, Ovarian
cancer scored as event (breast cancer considered as unaffected).
c, Breast cancer scored as event (ovarian cancer considered as
unaffected).
were performed in a GeneAmp System 7600 cycler (PE-
AB) at 94C , 60C, and 72C, for 30 s at each step.
The resulting two fragments were subjected to gel elec-
trophoresis after denaturation by means of the Alf Ex-
press system (Pharmacia Biotech) for 160 min, and
both fragments were scored for single insertions or de-
letions (i.e., fragments with primer BRCA1A/B or
1675U/L, respectively).
Sequencing.—After identification of probable mu-
tants, the verification procedure consisted of sequencing
of a PCR product. The PCR amplification was per-
formed under the same conditions, with some modifi-
cations. The two fragments were amplified separately,
either by means of 50 pmol of non–Cy5-labeled primers
BRCA1A and BRCA1B, for insA1135, or by means of
a different primer set, 11624 and 11716, for delA1675.
The 25 PCR cycles were performed at 94C, 55C, and
72C, for 30 s at each step. Cycle sequencing was per-
formed with 1 ml of PCR product, by means of a Thermo
Sequenase 7-deaza-dGTP kit (Amersham Life Sciences).
The 30 PCR cycles were performed at 94C for 45 s, at
58C for 45 s, and at 72C for 30 s. For 1135insA the
BRCA1A primers was 5′-Cy5-labeled, and for 1675delA
the 1675L primer was 5′-Cy5-labeled. Electrophoresis of
the sequencing products was performed by means of the
Alf Express, under the same conditions as were used for
fragment analysis.
Primer sequences.—The primer sequences were as
follows (where the BRCA1 cDNA base numbering is
from the start codon [A = 1]): BRCA1A (950), 5′-
Cy5 -AACATAACAGATGGGCTGGAAGT-3 ′ ;
BRCA1B ( 1 0 9 0 ) , 5 ′ - GATTCTCTGAGCA -
TGGCAGTTTC-3 ′; 1675U (1524), 5 ′-TACAT-
CAGGCCTTCATCCT-3′; 1675L (1587), 5′-Cy5-AG-
GAGTCTTTTGAACTGC-3 ′ ; 11624 (1505) ,
5 ′-TAAAGCGTAAAAGGAGAC-3 ′; and 11716
(1614), 5′-TTGGTTAGTTCCCTGATT-3′.
Results
Altogether, 74 cases of breast cancer and 93 cases of
ovarian cancer were noted in 156 women. Of the 93
cases of ovarian cancer, 75 were verified, by histology
reports, as epithelial cancer; the remaining 18 cases of
ovarian cancer were clinically described and had the
same age at onset as the 75 histologically verified cases
(data not shown); and all 93 cases were grouped together
as cases of ovarian cancer, for further analyses.
Eleven of the women had both breast cancer and ovar-
ian cancer. Three patients with breast cancer at ages 42,
51, and 52 years and one with ovarian cancer at age 40
years were mutation negative on testing; they were all
from the family cancer-clinic series.
Table 1 details the overall findings. Breast cancer and
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Figure 3 Age-related penetrance in the combined series, includ-
ing demonstrated mutation carriers and obligate carriers only, with
index cases excluded.
Table 2
Mutation-Carrier Status in Different Age Groups, for All Sisters in Sibships with Demonstrated,
Affected, or Obligate Carriers
AGE
(years)
NO. OF MUTATIONS DEMONSTRATED (NO. OF
INDEX CASES)/NO. IN WHOM MUTATIONS








29 0( 0)/0/ 1 3/ 5/ 7 3( 0)/ 5/ 8 .38 2.66
30–39 5( 8)/0/ 18 11/ 6/ 6 16( 8)/ 6/ 24 .65 3.9
40–49 6(12)/0/ 45 11/ 6/ 6 17(12)/ 6/ 51 .65 3.9
50–59 1( 6)/0/ 29 2/ 6/11 3( 6)/ 6/ 40 .25 2.75
60–69 1( 3)/0/ 11 2/ 5/ 6 3( 3)/ 5/ 17 .29 1.74
70 0( 1)/0/ 5 1/ 2/28 1( 1)/ 2/ 33 .33 9.24
Overall 13(30)/0/109 30/30/64 43(30)/30/173 .50 24.19b
a Number of untested unaffected multiplied by observed proportion of carriers among tested un-
affected in same age group.
b The four mutation-negative affected (phenocopies) are not included in this table; therefore, the
total is 4 less than that shown in table 1.
ovarian cancer are specified as they correspond with fig-
ures 1b and c and 2b and c. Also, the four phenocopies
are included. Thus, the sum of cancer cases was 152
affected with breast or ovarian cancer (carriers or un-
tested)  11 with both breast cancer and ovarian cancer
 4 phenocopies = 167. The 152 affected women had
124 unaffected sisters; 96 of these 124 unaffected sisters
were alive, 60 (63%) of whom were tested, and 30
(50%) of whomwere found to be carriers. Table 2 details
carrier status according to age.
Differences between the two mutations were sought
in carriers (demonstrated, affected, or obligate). As can
be seen in figure 1, no differences were found. The two
mutations were therefore grouped together for the rest
of the analyses.
Differences according to selection of families were
then sought in carriers (demonstrated, affected, or ob-
ligate) (fig. 2). As expected, an overrepresentation of
early-onset breast cancer was seen in the family cancer-
clinic series (log-rank ). Removal of the indexP = .04
cases made this difference disappear. In the series
grouped together as one series (index cases excluded),
the median age at onset was 49.5 years; when the cal-
culation considered demonstrated mutation carriers and
obligate carriers only, the median age at onset was 53.5
years (fig. 3).
Table 3 gives the final estimates of penetrances, ac-
cording to age. In column A, carriers (demonstrated,
affected, or obligate) were considered. In the results pre-
sented in column B, all untested unaffected sisters (dead
or alive) were considered to be carriers. Thus, column
A gives the maximum penetrance, and column B the
minimum penetrance, that could be derived from the
present series. Then the proportions of healthy sisters in
each age group who were demonstrated to be carriers/
noncarriers were used to calculate the figures in column
C, as the interpolated estimate between the results in
column A and those in column B.
Discussion
We identified 152 affected individuals, and only 3 un-
affected mutation carriers, who were 60 years of
age—that is, regardless of the way in which we looked
at the data by excluding index persons and by assuming
different degrees of intermediate/truncate selection with
regard to the estimation of the probability that untested
unaffected sisters were carriers, the calculated pene-
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Table 3
Cumulative Age-Related Penetrances of Breast and/or Ovarian Cancer (Whichever Came First) in Carriers (Demonstrated, Affected or
Obligate) and in Their Unaffected Sisters Not Tested
AGE
(years)
PROPORTION AFFECTED (AFTER REMOVAL OF ONE INDEX CASE PER FAMILY)
A: Mutation Carriersa
B: Category A with the Assumption
That All Unaffected Sisters Not




























29 .006  .006 .005  .005 .005 (.005)
30–39 .15  .030 1.4 .13  .023 1.3 .14 (.15) 1.4 (1.4)
40–49 .53  .044 3.8 .40  .037 2.7 .48 (.46) 3.4 (3.2)
50–59 .80  .036 2.7 .62  .039 2.2 .67 (.67) 1.9 (2.1)
60–69 .90d  .029 1.0 .70e  .039 .8 .76 (.73) .9 (.8)
a Results are from Kaplan-Meier calculations. Demonstrated, affected, and obligate mutation carriers are included.
b Results are from Kaplan-Meier calculations and includes all unaffected sisters not tested but assumed to be carriers, regardless of whether
they are dead or alive.
c Based on probabilities, given in table 2, that untested unaffected sisters are carriers. Data in parentheses are for consecutive ovarian-cancer
series only.
d Increasing to .97 at age 81 years (which is not included in table because of low numbers for calculations and possible phenocopies at high
age).
e Increasing to .76 at age 81 years (which is not included in table because of low numbers for calculations and possible phenocopies at high
age).
trance was high but was subject to fluctuation in small
numbers of individuals 150 years of age. Of the 137
sisters !50 years of age, 75 (55%) were affected. Cal-
culated numbers of phenocopies in this groupwere fewer
than three, potentially reducing the incidence of muta-
tion-associated disease to 53%. Thus, calculated pene-
trance at age 50 years was considered robust with
respect to phenocopies; at age 150 years, both pheno-
copies and fluctuation in small numbers may have in-
fluenced the results. We found it inappropriate to cal-
culate penetrance at age 169 (table 3) and did, in this
way, exclude from the calculations the five oldest indi-
viduals with cancer.
Our calculated penetrances seems to be higher than
those in previous reports of other frequent mutations
(Levy-Lahad et al. 1997; Struewing et al. 1997; Fodor
et al. 1998). Because of the limited numbers of individ-
uals included in them, most reports have wide confidence
limits for the calculated penetrances. Conclusions about
the differences between the reported series may not be
made until more data become available; meanwhile, one
may discuss a number of factors potentially influencing
the estimated penetrances.
Ascertainment
Under the assumption of single selection, the index
patient is excluded, and 50% of the sisters are expected
to be mutation carriers.We have identifiedmany families
in a small population and should have intermediate se-
lection. In such a situation, fewer than half the sisters
are expected to be carriers. Also, because the index per-
son is affected, another mutation-carrying sister would
be less likely to be affected. The lower the penetrance,
and the smaller the sibships, the more pronounced this
effect would be. When the penetrance is examined, it is
not valid to use penetrance estimates to select individuals
for analyses and then to use the same individuals to
establish the original penetrance estimate. For these rea-
sons, not only the index patients but all their sisters
should be excluded. It may be that some previous reports
have underestimated penetrance when sisters are not ex-
cluded. In our family cancer-clinic series, most affected
individuals were initially known and were used for as-
certainment. It follows that the whole branch of the
family should be excluded before analysis. These argu-
ments led to the same conclusions as have been presented
above: we tested all available unaffected sisters to de-
termine their carrier status, made no assumptions about
the ascertainment model, and used the observed pro-
portions of mutation-carrying sisters, categorized ac-
cording to age, for our calculations.
Paternal Inheritance
In half the cases, the mutation was expected to be
inherited from the father. Because of the sex-limitation
character of the trait, the clinical criteria for selection of
families are less sensitive for paternal inheritance. If the
mother or one of her close relatives in such a situation
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Figure 4 Age-related penetrances of BRCA1 1675delA and
1135insA in the consecutive ovarian-cancer series. Only mutation car-
riers (demonstrated, affected, or obligate) are included; index cases
are excluded. a, Ovarian cancer scored as event (patients with breast
cancer censored at age at diagnosis). b, Breast cancer scored as event
(patients with ovarian cancer censored at age at diagnosis).
were to be affected (phenocopies), that part of the family
may be interpreted as containing the mutation. This ef-
fect may erroneously reduce the calculated penetrance.
The father’s family has to be extensively examined also
when the mother and/or her relatives are affected. This
problem was expected to occur in the family cancer-
clinic cases, and phenocopies were actually found in 4
(29%) of 14 of these families, all on the mother’s side.
Extension of Families
If families are extended laterally enough, the problems
merge with the concept of ascertainment: eventually,
truncate selection for our founder mutations may be
reached, and the problems will be solved. In truncate
selection, we cannot exclude the index branches—there
would be nothing left.
Informative Censoring
If a mutation carrier dies of ovarian cancer, she cannot
contract breast cancer afterward. Both the penetrance
of breast cancer or ovarian cancer, considered separately,
and the prevalence of both breast cancer and ovarian
cancer occurring in the same person are influenced by
the probability that that person survives the first cancer.
The problem is known as informative censoring, and
“there is no satisfactory way to compare survival times
of two or more groups of patients in the presence of
informative censoring” (Collett 1994, p. 274). This
problem has been extensively discussed in relation to
inherited retinoblastoma, which also may serve as an
example of modified second-cancer risk in relation to
treatment for the first cancer. With the improvement in
treatment results, it is to be expected that penetrances
for both breast cancer and ovarian cancer, considered
separately, are increasing, as is the prevalence of affected
individuals with both types of cancer. Retrospective re-
ports from different countries reflect different popula-
tions, different mutations, and different environments,
as well as international differences between health care
available today and that available generations ago. Scor-
ing as affected/unaffected and including both breast
cancer and ovarian cancer as affected may be the most
robust parameter for penetrance, as well as for com-
parisons between series. When column A of table 3 and
figure 4b are compared, it is seen that the penetrance in
mutation carriers 69 years of age was reduced, from
90% to 54%, when only cases of breast cancer were
counted and when there was censoring with regard to
age at onset of ovarian cancer (penetrance for the con-
secutive ovarian-cancer series alone, according to the
data in column A of table 3, was 82% [data not shown]);
these may be considered two extreme results obtained
in the present study, indicating that it is possible that
methodological problems may explain some of the dif-
ferences between previous reports. Since figure 4 is based
on consecutive ovarian-cancer series only, we recalcu-
lated table 3 for that series separately. The results are
given in column C of table 3, for comparison. They seem
to be identical to the results for the combined series,
indicating that there is no problem of fluctuating results
due to small numbers and that there are no major dis-
crepancies, between the series, due to ascertainment
problems. The results indicate that, in our series, infor-
mative censoring was a problem, whereas the ascertain-
ment differences had less impact.
678 Am. J. Hum. Genet. 65:671–679, 1999
Differences between the Series
Except for the early-onset cases of breast cancer that
were used to ascertain the family cancer-clinic series, we
found no difference between the two series. This may
be an indication that the problems discussed above have
no major impact on the estimated penetrances; however,
the problems are complex, and such an interpretation
must be regarded with extreme caution. As mentioned,
some of the problems discussed are less important when
penetrance is high.
Modifiers of Penetrance
The families lived geographically separate, and they
were so distant genetically that they may not have shared
many factors other than the mutation-carrying BRCA1
haplotype. Theoretically, frequent genetic and/or envi-
ronmental modifying factors could be present in our
population and not elsewhere. Such putative endemic/
ethnic factors have, however, not been described.
Breast Cancer versus Ovarian Cancer
The families contained more verified cases of ovarian
cancer than the total number of reported breast cancers;
after removal of the 16 index cases in the consecutive
ovarian-cancer series, this was still the case. This result
is in contrast to those in previous reports, but it is com-
patible with theoretical analyses of the initial families
reported by the Breast Cancer Linkage Consortium
(Easton 1995). This favors a “true” high expression of
ovarian cancer as affected phenotype, and it seems to
argue against the putative hypothesis that ascertainment
of families through ovarian cancer as an infrequent ex-
pression of the trait results in selection of families with
additional factors causing generally increased pene-
trance. If additional factors modified the expression
from breast cancer to ovarian cancer, then the propor-
tion of ovarian cancers would decrease with increasing
genetic distance to the proband. The series was consid-
ered insufficient for analysis of this problem, which will
be addressed in further studies.
Random Segregation
After removal of one index person in each of the 30
families that we studied, the sibships contained 246
women. Of these, 122 were affected, 30 were unaffected
and mutation carriers, and 24.19 were unaffected un-
tested and were calculated to be carriers (table 2); the
sum is 176.19, which is more than the 123 (50%) ex-
pected ( , ). The observation of the2x = 23.0 P ! .00001
same number of carriers as noncarriers among the tested
unaffected sisters may indicate preferential segregation
of the mutation-carrying haplotypes. Neither selection
nor genetic drift is expected to produce such a finding;
however, because most the affected individuals had died
and were unavailable for mutation testing (see above),
the question of putative preferential segregation remains
unanswered. The findings may also be explained as an
indication of a “true” low penetrance. For these reasons,
we differentiated the untested unaffected sisters accord-
ing to possible carrier status, without assuming random
segregation of the mutations (table 3).
One practical reason for the present report is that we
are performing predictive mutation testing in the healthy
sisters. We had to know the predictive value of dem-
onstrating the carrier status in healthy women in these
families. We will use the results for genetic counseling
in families ascertained as described.
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